Zacks Investment Research upgraded shares of Quanterix (NASDAQ:QTRX) from a sell rating to a hold rating in a research report report published on Tuesday.

According to Zacks, “Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. The company services include Simoa Accelerator Lab and custom assay development services. Quanterix Corporation is based in LEXINGTON, United States. “

Several other research firms have also recently weighed in on QTRX. BTIG Research restated a buy rating and set a $26.00 price target on shares of Quanterix in a report on Sunday, May 13th. ValuEngine upgraded shares of Quanterix from a hold rating to a buy rating in a report on Monday, June 11th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Quanterix presently has an average rating of Buy and an average price target of $26.50.

NASDAQ:QTRX opened at $15.50 on Tuesday. The stock has a market cap of $369.73 million and a PE ratio of -1.95. Quanterix has a one year low of $13.00 and a one year high of $24.81.

Quanterix (NASDAQ:QTRX) last posted its earnings results on Friday, August 10th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.06). The firm had revenue of $8.64 million for the quarter, compared to the consensus estimate of $7.92 million. research analysts anticipate that Quanterix will post -1.2 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC boosted its holdings in Quanterix by 1.8% during the second quarter. Jennison Associates LLC now owns 351,831 shares of the company’s stock worth $5,052,000 after purchasing an additional 6,170 shares during the last quarter. California State Teachers Retirement System purchased a new position in Quanterix during the first quarter worth about $129,000. Acadian Asset Management LLC purchased a new position in Quanterix during the second quarter worth about $117,000. First Republic Investment Management Inc. purchased a new position in Quanterix during the second quarter worth about $235,000. Finally, Bank of New York Mellon Corp purchased a new position in Quanterix in the second quarter valued at about $312,000. Institutional investors and hedge funds own 49.14% of the company’s stock.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer.

Recommended Story: Google Finance Portfolio Tips and Tricks

Get a free copy of the Zacks research report on Quanterix (QTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.